TrialReader


Effect of Acotiamide on Gastric Motility and Satiation in Healthy Volunteers

NCT03402984 — Not applicable, Completed, 20 participants, Universitaire Ziekenhuizen KU Leuven

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Acotiamide Affects Antral Motility, But Has no Effect on Fundic Motility, Gastric Emptying or Symptom Perception in Healthy Participants

RegistryNCT03402984
StatusCompleted
PhaseNot applicable
Study typeInterventional; randomized, crossover, masking: single, other
Enrollment20 (Actual)
SponsorUniversitaire Ziekenhuizen KU Leuven (Other)
ConditionsHealthy
InterventionsAcotiamide, Placebo Oral Tablet (Drug)
Datesstart 2017-04-01, primary completion 2017-07-30, completion 2017-12-04, first posted 2018-01-18, last updated 2018-01-18
Locations1 site in Belgium

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Healthy All trials of Acotiamide All trials of Placebo Oral Tablet

-Summary

Introduction. Functional dyspepsia (FD) is a common chronic gastrointestinal disorder with a high socio-economic impact. Acotiamide, a new prokinetic agent, was shown to be efficacious in the treatment of FD, especially in the postprandial distress syndrome subgroup. To date, the exact mechanism of action of acotiamide is incompletely elucidated.

The aim of this study was to examine the effect of acotiamide on gastric motility, gastric emptying rate and gastrointestinal symptom perception in healthy participants in a randomized, placebo-controlled, cross-over study design. Participants were treated with acotiamide (100 mg t.i.d.) and placebo for 3 weeks, separated by a one-week wash-out period. At the end of each treatment period, gastric emptying and motility were assessed on two consecutive study days. During gastric motility assessment, epigastric symptom scores were collected at multiple time points.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
AcotiamideExperimentalDrug: AcotiamideAcotiamide 100 mg t.i.d. for 3 weeks. Intake of medication 10 minutes before meal.
PlaceboPlacebo comparatorDrug: Placebo Oral TabletPlacebo tablets, t.i.d. for 3 weeks. Intake of placebo 10 minutes before meal.
  • Acotiamide (Drug): Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.
  • Placebo Oral Tablet (Drug): Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.

+Outcome measures

Primary outcomes

  • Gastric accommodation [Gastric pressure was measured until 1 hour after the start of the liquid meal. Liquid meal started 10 minutes after medication/placebo intake]: Relaxation of the stomach upon food intake

Secondary outcomes

  • Gastric emptying [Breath samples were collected before intake of medication/placebo and every 15 minutes until 4h after intake of 13C-octanoid acid]: Gastric emptying was assess by a 13C-octanoid acid breath test
  • Change in subjective gastrointestinal symptom scores measured by visual analogue scale of 100 mm [assessment by questionnaire (100 mm Visual Analogue Scale) every 5 minutes, up to 1 hour after administration of the liquid meal]

+Eligibility

Sex: All, ages: 18 Years to 60 Years, accepts healthy volunteers

Inclusion Criteria:

* age: 18-60 years old.
* Participant must provide witnessed written informed consent prior to any study procedures being performed.

Exclusion criteria:

* Age > 60 years old.
* severely decreased kidney function.
* severely decreased liver function.
* severe heart disease, for example a history of irregular heartbeats, angina or heart attack.
* severe lung disease.
* severe psychiatric illness or neurological illness.
* any gastrointestinal disease.
* any dyspeptic symptoms.
* pregnant or breastfeeding.

+Locations (1)

FacilityCityCountryStatus
Jan TackLeuvenBelgium

+Publications

  • Results publication: Masuy I, Tack J, Verbeke K, Carbone F. Acotiamide affects antral motility, but has no effect on fundic motility, gastric emptying or symptom perception in healthy participants. Neurogastroenterol Motil. 2019 Apr;31(4):e13540. doi: 10.1111/nmo.13540. Epub 2019 Jan 20. PMID 30663175

+Investigators

My Notes